Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotic Assistance

This article was originally published in RPM Report

Executive Summary

The drug safety/user fee bill working its way through Congress has some surprising benefits for antibiotic drug developers, and a voucher scheme to let companies developing drugs for tropical diseases earn the right to faster FDA reviews for more commercially attractive products.

You may also be interested in...



Antibiotic Incentive Bill Reintroduced: Industry Hopes for 2012 Enactment

The bill focuses on particularly virulent, resistant pathogens and also includes priority review designations and review of FDA guidelines.

Forest Labs Had Effective "Co-Sponsor" for Ceftaroline Review

FDA got a chance to show off its ability to stimulate antibiotic development during an advisory committee review of a new cephalosporin from Forest Labs. In the past, the agency has been faulted for failing to set clear targets for anti-infective trials; with ceftaroline, the agency went to the other extreme, stepping in to support an application with key re-analyses of data.

Treat and Trade: The New Priority Review Voucher Market

This is a reprint of the feature of the same title appearing in the July 2008 issue of The RPM Report.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS080282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel